Moximed closed on $61 million of Series D preferred stock financing with an option to close on up to an additional $30 million.
Proceeds will be used to accelerate U.S. commercialization of Moximed’s MISHA Knee, the world’s first implantable shock absorber (ISA) for knee osteoarthritis. Implanted during an outpatient procedure, MISHA has been shown to alleviate pain, improve function and delay the need for total knee replacement in some patients.
“This financing is validation of the significant market opportunity for the MISHA Knee System,” said Chris Gleason, President and Chief Executive Officer of Moximed. “We are seeing tremendous interest from surgeons and patients, and we are excited to rapidly expand our commercial infrastructure to address evolving patient needs in this growing market.”
Moximed closed on $61 million of Series D preferred stock financing with an option to close on up to an additional $30 million.
Proceeds will be used to accelerate U.S. commercialization of Moximed’s MISHA Knee, the world’s first implantable shock absorber (ISA) for knee osteoarthritis. Implanted during an outpatient procedure, MISHA has been...
Moximed closed on $61 million of Series D preferred stock financing with an option to close on up to an additional $30 million.
Proceeds will be used to accelerate U.S. commercialization of Moximed’s MISHA Knee, the world’s first implantable shock absorber (ISA) for knee osteoarthritis. Implanted during an outpatient procedure, MISHA has been shown to alleviate pain, improve function and delay the need for total knee replacement in some patients.
“This financing is validation of the significant market opportunity for the MISHA Knee System,” said Chris Gleason, President and Chief Executive Officer of Moximed. “We are seeing tremendous interest from surgeons and patients, and we are excited to rapidly expand our commercial infrastructure to address evolving patient needs in this growing market.”
Copy to clipboard 
